fr

CARMAT announces the resumption of commercial implants of its Aeson® artificial heart is now effective

Share post

CARMAT announces the resumption of commercial implants of its Aeson® artificial heart is now effective

November 21st 2022

Paris, November 21, 2022 – 7 am CET

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced that the resumption of commercial implants of its Aeson® artificial heart is now effective

On October 25, CARMAT announced that the DEKRA notified body had approved all the changes implemented on Aeson®, thus allowing the Company to resume commercial implants in the European Union and other countries that recognize CE Marking.

In view of this, a first commercial implant of Aeson® was performed in a German hospital last week. The Company reminds readers that implants will continue to resume at a gradual pace in line with the rebuilding of its inventory of implantable prostheses.

In accordance with the principles it has consistently applied, the Company does not plan to communicate on the state of health of individual patients nor on the performance of each implantation. CARMAT will continue to communicate on its progress when it reaches significant milestones and when it publishes its financial results.

Stéphane Piat, Chief Executive Officer of CARMAT, said:The resumption of implants was eagerly awaited by many physicians, and we are delighted that European patients are able to benefit from our therapy again. In accordance with our roadmap, we continue to rebuild our inventory of prostheses, paying particular attention to quality control, in order to be in a position to gradually meet demand from medical centers, both in a commercial setting and within the framework of our clinical trials”.

 

About CARMAT

CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company’s ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d’Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of more than 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956).

For more information, please go to www.carmatsa.com and follow us on LinkedIn.

 

 

 

CARMAT

Stéphane Piat

Chief Executive Officer

 

Pascale d’Arbonneau

Chief Financial Officer

Tel.: +33 1 39 45 64 50

contact@carmatsas.com

 

 

 

Alize RP

Press Relations

 

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

carmat@alizerp.com

NewCap

Financial Communication
& Investor Relations

 

Dusan Oresansky

Quentin Massé

Tel.: +33 1 44 71 94 92

carmat@newcap.eu

 

 

 

 

 

 

Name: CARMAT

ISIN code: FR0010907956

Ticker: ALCAR

 

 

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT (the “Company”) in any country. This press release may contain forwardlooking statements that relate to the Company’s objectives and prospects. Such forwardlooking statements are based solely on the current expectations and assumptions of the Company’s management and involve risk and uncertainties including, without limitation, the Company’s ability to successfully implement its strategy, the rate of development of CARMAT’s production and sales, the pace and results of ongoing and future clinical trials, new products or technological developments introduced by competitors, changes in regulations and risks associated with growth management. The Company’s objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.

The significant and specific risks pertaining to the Company are those described in the Universal Registration Document (“Document d’Enregistrement Universel”) filed with the Autorité des Marchés Financiers (AMF, the French stock market authorities) under number D. 22-0332. Readers and investors’ attention is, however, drawn to the fact that other risks, unknown or not deemed to be significant or specific, may or could exist.

 

Aeson® is an active implantable medical device commercially available in the European Union and other countries that recognize CE marking. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients suffering from end-stage biventricular heart failure (INTERMACS classes 1-4) who are not amenable to maximal medical therapy or a left ventricular assist device (LVAD) and are likely to undergo a heart transplant within 180 days of the device being implanted. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician manual, patient manual and alarm booklet) should be read carefully to understand the characteristics of Aeson® and information necessary for patient selection and the proper use of Aeson® (contraindications, precautions, side effects). In the United States, Aeson® is currently exclusively available within the framework of an Early Feasibility Study authorized by the Food & Drug Administration (FDA).

Top of page